Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases

  • Schäfer, Samuel
  • Smelik, Martin
  • Sysoev, Oleg
  • Zhao, Yelin
  • Eklund, Desiré
  • Lilja, Sandra
  • Gustafsson, Mika
  • Heyn, Holger
  • Julià, Antonio
  • Kovács, István A.
  • Loscalzo, Joseph
  • Marsal Barril, Sara
  • Zhang, Huan
  • Li, Xinxiu
  • Gawel, Danuta
  • Wang, Hui
  • Benson, Mikael
Background: Ineffective drug treatment is a major problem for many patients with immune-mediated inflammatory diseases (IMIDs). Important reasons are the lack of systematic solutions for drug prioritisation and repurposing based on characterisation of the complex and heterogeneous cellular and molecular changes in IMIDs. Methods: Here, we propose a computational framework, scDrugPrio, which constructs network models of inflammatory disease based on single-cell RNA sequencing (scRNA-seq) data. scDrugPrio constructs detailed network models of inflammatory diseases that integrate information on cell type-specific expression changes, altered cellular crosstalk and pharmacological properties for the selection and ranking of thousands of drugs. Results: scDrugPrio was developed using a mouse model of antigen-induced arthritis and validated by improved precision/recall for approved drugs, as well as extensive in vitro, in vivo, and in silico studies of drugs that were predicted, but not approved, for the studied diseases. Next, scDrugPrio was applied to multiple sclerosis, Crohn's disease, and psoriatic arthritis, further supporting scDrugPrio through prioritisation of relevant and approved drugs. However, in contrast to the mouse model of arthritis, great interindividual cellular and gene expression differences were found in patients with the same diagnosis. Such differences could explain why some patients did or did not respond to treatment. This explanation was supported by the application of scDrugPrio to scRNA-seq data from eleven individual Crohn's disease patients. The analysis showed great variations in drug predictions between patients, for example, assigning a high rank to anti-TNF treatment in a responder and a low rank in a nonresponder to that treatment. Conclusions: We propose a computational framework, scDrugPrio, for drug prioritisation based on scRNA-seq of IMID disease. Application to individual patients indicates scDrugPrio's potential for personalised network-based drug screening on cellulome-, genome-, and drugome-wide scales. For this purpose, we made scDrugPrio into an easy-to-use R package ( https://github.com/SDTC-CPMed/scDrugPrio )., Open access funding provided by Karolinska Institute. This work was supported by the DocTIS project, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement N° 848028; Swedish Cancer Society CAN 2017/411; Cocozza Foundation; National Natural Science Foundation of China 82171791, US National Institutes of Health grants HL155107 and HL155096; American Heart Association grant 957729; European Union’s Horizon 2021 Research and Innovation Programme grant 101057619 and Mag-Tarmfonden (grant 1–23). The computations were partially enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Linköping University partially funded by the Swedish Research Council through grant agreement no. 2018–05973.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease

  • Garrido Trigo, Alba
  • Marchese, Domenica, 1986-
  • Caratù, Ginevra
  • Heyn, Holger
  • Salas, Azucena
Ulcerative colitis and Crohn's disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity., This work was funded by grant PID2021-123918OB-I00 from MCIN/AEI/ 10.13039/501100011033 and co-funded by “FEDER A way to make Europe”. AM-C, VG and ID were funded by grant Grant #2008-04050 from The Leona and Harry B. Helmsley Charitable Trust. EM-A is funded by grant RH042155 (RTI2018-096946-B-I00) from Ministerio de Ciencia e Innovacion. IA-T is funded by grant 831434-2 (CE_IMI2-2018-14 call). HH received support for the project PID2020-115439GB-I00- funded by MCIN/AEI/10.13039/501100011033. This publication is part of a project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434. This project also has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848028.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease

  • Garrido-Trigo, Alba
  • Corraliza, Ana M.
  • Veny, Marisol
  • Dotti, Isabella
  • Melón-Ardanaz, Elisa
  • Rill, Aina
  • Crowell, Helena L.
  • Corbí, Angel L.
  • Gudiño, Victoria
  • Esteller, Miriam
  • Álvarez-Teubel, Iris
  • Aguilar, Daniel
  • Masamunt, M. Carme
  • Killingbeck, Emily
  • Kim, Youngmi
  • Leon, Michael
  • Visvanathan, Sudha
  • Marchese, Domenica
  • Caratù, Ginevra
  • Martin-Cardona, Albert
  • Esteve, Maria
  • Ordás, Ingrid
  • Panés, Julián
  • Ricart, Elena
  • Mereu, Elisabetta
  • Heyn, Holger
  • Salas, Azucena
18 p.-6 fig., Ulcerative colitis and Crohn’s disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity., This work was funded by grant PID2021-123918OB-I00 from MCIN/AEI/ 10.13039/501100011033 and co-funded by “FEDER A way to make Europe”. AM-C, VG and ID were funded by grant Grant #2008-04050 from The Leona and Harry B. Helmsley Charitable Trust. EM-A is funded by grant RH042155 (RTI2018-096946-B-I00) from Ministerio de Ciencia e Innovacion. IA-T is funded by grant 831434-2 (CE_IMI2-2018-14 call). HH received support for the project PID2020-115439GB-I00- funded by MCIN/AEI/10.13039/501100011033. This publication is part of a project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434. This project also has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848028., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases

  • Schäfer, Samuel
  • Smelik, Martin
  • Sysoev, Oleg
  • Zhao, Yelin
  • Eklund, Desiré
  • Lilja, Sandra
  • Gustafsson, Mika
  • Heyn, Holger
  • Julià, Antonio
  • Kovács, István A.
  • Loscalzo, Joseph
  • Marsal Barril, Sara
  • Zhang, Huan
  • Li, Xinxiu
  • Gawel, Danuta
  • Wang, Hui
  • Benson, Mikael
Background: Ineffective drug treatment is a major problem for many patients with immune-mediated inflammatory diseases (IMIDs). Important reasons are the lack of systematic solutions for drug prioritisation and repurposing based on characterisation of the complex and heterogeneous cellular and molecular changes in IMIDs. Methods: Here, we propose a computational framework, scDrugPrio, which constructs network models of inflammatory disease based on single-cell RNA sequencing (scRNA-seq) data. scDrugPrio constructs detailed network models of inflammatory diseases that integrate information on cell type-specific expression changes, altered cellular crosstalk and pharmacological properties for the selection and ranking of thousands of drugs. Results: scDrugPrio was developed using a mouse model of antigen-induced arthritis and validated by improved precision/recall for approved drugs, as well as extensive in vitro, in vivo, and in silico studies of drugs that were predicted, but not approved, for the studied diseases. Next, scDrugPrio was applied to multiple sclerosis, Crohn's disease, and psoriatic arthritis, further supporting scDrugPrio through prioritisation of relevant and approved drugs. However, in contrast to the mouse model of arthritis, great interindividual cellular and gene expression differences were found in patients with the same diagnosis. Such differences could explain why some patients did or did not respond to treatment. This explanation was supported by the application of scDrugPrio to scRNA-seq data from eleven individual Crohn's disease patients. The analysis showed great variations in drug predictions between patients, for example, assigning a high rank to anti-TNF treatment in a responder and a low rank in a nonresponder to that treatment. Conclusions: We propose a computational framework, scDrugPrio, for drug prioritisation based on scRNA-seq of IMID disease. Application to individual patients indicates scDrugPrio's potential for personalised network-based drug screening on cellulome-, genome-, and drugome-wide scales. For this purpose, we made scDrugPrio into an easy-to-use R package ( https://github.com/SDTC-CPMed/scDrugPrio )., Open access funding provided by Karolinska Institute. This work was supported by the DocTIS project, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement N° 848028; Swedish Cancer Society CAN 2017/411; Cocozza Foundation; National Natural Science Foundation of China 82171791, US National Institutes of Health grants HL155107 and HL155096; American Heart Association grant 957729; European Union’s Horizon 2021 Research and Innovation Programme grant 101057619 and Mag-Tarmfonden (grant 1–23). The computations were partially enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Linköping University partially funded by the Swedish Research Council through grant agreement no. 2018–05973.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease

  • Garrido Trigo, Alba
  • Marchese, Domenica, 1986-
  • Caratù, Ginevra
  • Heyn, Holger
  • Salas, Azucena
Ulcerative colitis and Crohn's disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity., This work was funded by grant PID2021-123918OB-I00 from MCIN/AEI/ 10.13039/501100011033 and co-funded by “FEDER A way to make Europe”. AM-C, VG and ID were funded by grant Grant #2008-04050 from The Leona and Harry B. Helmsley Charitable Trust. EM-A is funded by grant RH042155 (RTI2018-096946-B-I00) from Ministerio de Ciencia e Innovacion. IA-T is funded by grant 831434-2 (CE_IMI2-2018-14 call). HH received support for the project PID2020-115439GB-I00- funded by MCIN/AEI/10.13039/501100011033. This publication is part of a project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434. This project also has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848028.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases

  • Schäfer, Samuel
  • Smelik, Martin
  • Sysoev, Oleg
  • ZHAO, YELIN
  • Eklund, Desiré
  • Lilja, Sandra
  • Julià Cano, Antonio
  • marsal, sara
Drug repurposing; Immune-mediated inflammatory disease; Single-cell RNA sequencing, Reutilización de medicamentos; Enfermedad inflamatoria inmunomediada; Secuenciación de ARN unicelular, Reutilització de medicaments; Malaltia inflamatòria immunomediada; Seqüenciació d'ARN unicel·lular, Background Ineffective drug treatment is a major problem for many patients with immune-mediated inflammatory diseases (IMIDs). Important reasons are the lack of systematic solutions for drug prioritisation and repurposing based on characterisation of the complex and heterogeneous cellular and molecular changes in IMIDs. Methods Here, we propose a computational framework, scDrugPrio, which constructs network models of inflammatory disease based on single-cell RNA sequencing (scRNA-seq) data. scDrugPrio constructs detailed network models of inflammatory diseases that integrate information on cell type-specific expression changes, altered cellular crosstalk and pharmacological properties for the selection and ranking of thousands of drugs. Results scDrugPrio was developed using a mouse model of antigen-induced arthritis and validated by improved precision/recall for approved drugs, as well as extensive in vitro, in vivo, and in silico studies of drugs that were predicted, but not approved, for the studied diseases. Next, scDrugPrio was applied to multiple sclerosis, Crohn’s disease, and psoriatic arthritis, further supporting scDrugPrio through prioritisation of relevant and approved drugs. However, in contrast to the mouse model of arthritis, great interindividual cellular and gene expression differences were found in patients with the same diagnosis. Such differences could explain why some patients did or did not respond to treatment. This explanation was supported by the application of scDrugPrio to scRNA-seq data from eleven individual Crohn’s disease patients. The analysis showed great variations in drug predictions between patients, for example, assigning a high rank to anti-TNF treatment in a responder and a low rank in a nonresponder to that treatment. Conclusions We propose a computational framework, scDrugPrio, for drug prioritisation based on scRNA-seq of IMID disease. Application to individual patients indicates scDrugPrio’s potential for personalised network-based drug screening on cellulome-, genome-, and drugome-wide scales. For this purpose, we made scDrugPrio into an easy-to-use R package (https://github.com/SDTC-CPMed/scDrugPrio)., Open access funding provided by Karolinska Institute. This work was supported by the DocTIS project, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement N° 848028; Swedish Cancer Society CAN 2017/411; Cocozza Foundation; National Natural Science Foundation of China 82171791, US National Institutes of Health grants HL155107 and HL155096; American Heart Association grant 957729; European Union’s Horizon 2021 Research and Innovation Programme grant 101057619 and Mag-Tarmfonden (grant 1–23). The computations were partially enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Linköping University partially funded by the Swedish Research Council through grant agreement no. 2018–05973.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19

  • Julia Cano, Antonio
  • Bonafonte Pardàs, Irene
  • Gomez Moruno, Antonio
  • Lopez Lasanta, Maria America
  • Lopez Corbeto, Mireia
  • Martinez Mateu, Sergio Hilario
  • Llados Segura, Jordi Francesc
  • Marsal Barril, Sara
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Malalties inflamatòries; Identificació de l'objectiu; Infecció viral, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Enfermedades inflamatorias; Identificación del objetivo; Infección viral, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammatory diseases; Target identification; Viral infection, An excessive immune response known as cytokine storm is the hallmark of severe COVID-19. The cause of this cytokine rampage is yet not known. Based on recent epidemiological evidence, we hypothesized that CD80/86 signaling is essential for this hyperinflammation, and that blocking this proinflammatory axis could be an effective therapeutic approach to protect against severe COVID-19. Here we provide exploratory evidence that abatacept, a drug that blocks CD80/86 co-stimulation, produces changes at the systemic level that are highly antagonistic of the proinflammatory processes elicited by COVID-19. Using RNA-seq from blood samples from a longitudinal cohort of n = 38 rheumatic patients treated with abatacept, we determined the immunological processes that are significantly regulated by this treatment. We then analyzed available blood RNA-seq from two COVID19 patient cohorts, a very early cohort from the epicenter of the pandemic in China (n = 3 COVID-19 cases and n = 3 controls), and a recent and larger cohort from the USA (n = 49 severe and n = 51 mild COVD-19 patients). We found a highly significant antagonism between SARS-CoV-2 infection and COVID-19 severity with the systemic response to abatacept. Analysis of previous single-cell RNA-seq data from bronchoalveolar lavage fluid from mild and severe COVID-19 patients and controls, reinforce the implication of the CD80/86 proinflammatory axis. Our functional results further support abatacept as a candidate therapeutic approach to prevent severe COVID-19., The PACTABA project was funded Bristol-Myers Squibb. We thank all participants from the PACTABA study for their collaboration. AJ and SM are supported by the DoCTIS project funded by the European Union’s H2020 programme (Grant #848028). This work was supported by funds from the Vall d’Hebron Hospital Research Institute and from IMIDomics S.L. We thank Dr Ariel Jaitovich (Albany Medical Centre, USA) for providing additional clinical data on the late COVID-19 cohort.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease

  • Garrido-Trigo, Alba
  • Corraliza, Ana Maria|||0000-0002-3067-7763
  • Veny, Marisol
  • Dotti, Isabella
  • Melón-Ardanaz, Elisa
  • Rill, Aina|||0000-0001-9885-0705
  • Crowell, Helena L.|||0000-0002-4801-1767
  • Corbí, Ángel|||0000-0003-1980-5733
  • Gudiño, Victoria
  • Esteller, Miriam
  • Álvarez-Teubel, Iris
  • Aguilar, Daniel
  • Masamunt, M.Carmen
  • Killingbeck, E.|||0000-0002-5108-5089
  • Kim, Youngmi
  • Leon, Michael|||0000-0003-3982-2063
  • Visvanathan, Sudha
  • Marchese, Domenica|||0000-0002-3036-4580
  • Caratù, Ginevra|||0000-0003-1085-8062
  • Martín Cardona, Albert|||0000-0002-7090-0106
  • Esteve, Maria|||0000-0001-7716-0027
  • Panés, Julián|||0000-0002-4971-6902
  • Ricart, Elena
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Heyn, Holger|||0000-0002-3276-1889
  • Salas, Azucena
Ulcerative colitis and Crohn's disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19

  • Julia Cano, Antonio
  • Bonafonte Pardàs, Irene
  • Gomez Moruno, Antonio
  • Lopez Lasanta, Maria America
  • Lopez Corbeto, Mireia
  • Martinez Mateu, Sergio Hilario
  • Llados Segura, Jordi Francesc
  • Marsal Barril, Sara
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Malalties inflamatòries; Identificació de l'objectiu; Infecció viral, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Enfermedades inflamatorias; Identificación del objetivo; Infección viral, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammatory diseases; Target identification; Viral infection, An excessive immune response known as cytokine storm is the hallmark of severe COVID-19. The cause of this cytokine rampage is yet not known. Based on recent epidemiological evidence, we hypothesized that CD80/86 signaling is essential for this hyperinflammation, and that blocking this proinflammatory axis could be an effective therapeutic approach to protect against severe COVID-19. Here we provide exploratory evidence that abatacept, a drug that blocks CD80/86 co-stimulation, produces changes at the systemic level that are highly antagonistic of the proinflammatory processes elicited by COVID-19. Using RNA-seq from blood samples from a longitudinal cohort of n = 38 rheumatic patients treated with abatacept, we determined the immunological processes that are significantly regulated by this treatment. We then analyzed available blood RNA-seq from two COVID19 patient cohorts, a very early cohort from the epicenter of the pandemic in China (n = 3 COVID-19 cases and n = 3 controls), and a recent and larger cohort from the USA (n = 49 severe and n = 51 mild COVD-19 patients). We found a highly significant antagonism between SARS-CoV-2 infection and COVID-19 severity with the systemic response to abatacept. Analysis of previous single-cell RNA-seq data from bronchoalveolar lavage fluid from mild and severe COVID-19 patients and controls, reinforce the implication of the CD80/86 proinflammatory axis. Our functional results further support abatacept as a candidate therapeutic approach to prevent severe COVID-19., The PACTABA project was funded Bristol-Myers Squibb. We thank all participants from the PACTABA study for their collaboration. AJ and SM are supported by the DoCTIS project funded by the European Union’s H2020 programme (Grant #848028). This work was supported by funds from the Vall d’Hebron Hospital Research Institute and from IMIDomics S.L. We thank Dr Ariel Jaitovich (Albany Medical Centre, USA) for providing additional clinical data on the late COVID-19 cohort.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases

  • Schäfer, Samuel
  • Smelik, Martin
  • Sysoev, Oleg
  • ZHAO, YELIN
  • Eklund, Desiré
  • Lilja, Sandra
  • Julià Cano, Antonio
  • marsal, sara
Drug repurposing; Immune-mediated inflammatory disease; Single-cell RNA sequencing, Reutilización de medicamentos; Enfermedad inflamatoria inmunomediada; Secuenciación de ARN unicelular, Reutilització de medicaments; Malaltia inflamatòria immunomediada; Seqüenciació d'ARN unicel·lular, Background Ineffective drug treatment is a major problem for many patients with immune-mediated inflammatory diseases (IMIDs). Important reasons are the lack of systematic solutions for drug prioritisation and repurposing based on characterisation of the complex and heterogeneous cellular and molecular changes in IMIDs. Methods Here, we propose a computational framework, scDrugPrio, which constructs network models of inflammatory disease based on single-cell RNA sequencing (scRNA-seq) data. scDrugPrio constructs detailed network models of inflammatory diseases that integrate information on cell type-specific expression changes, altered cellular crosstalk and pharmacological properties for the selection and ranking of thousands of drugs. Results scDrugPrio was developed using a mouse model of antigen-induced arthritis and validated by improved precision/recall for approved drugs, as well as extensive in vitro, in vivo, and in silico studies of drugs that were predicted, but not approved, for the studied diseases. Next, scDrugPrio was applied to multiple sclerosis, Crohn’s disease, and psoriatic arthritis, further supporting scDrugPrio through prioritisation of relevant and approved drugs. However, in contrast to the mouse model of arthritis, great interindividual cellular and gene expression differences were found in patients with the same diagnosis. Such differences could explain why some patients did or did not respond to treatment. This explanation was supported by the application of scDrugPrio to scRNA-seq data from eleven individual Crohn’s disease patients. The analysis showed great variations in drug predictions between patients, for example, assigning a high rank to anti-TNF treatment in a responder and a low rank in a nonresponder to that treatment. Conclusions We propose a computational framework, scDrugPrio, for drug prioritisation based on scRNA-seq of IMID disease. Application to individual patients indicates scDrugPrio’s potential for personalised network-based drug screening on cellulome-, genome-, and drugome-wide scales. For this purpose, we made scDrugPrio into an easy-to-use R package (https://github.com/SDTC-CPMed/scDrugPrio)., Open access funding provided by Karolinska Institute. This work was supported by the DocTIS project, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement N° 848028; Swedish Cancer Society CAN 2017/411; Cocozza Foundation; National Natural Science Foundation of China 82171791, US National Institutes of Health grants HL155107 and HL155096; American Heart Association grant 957729; European Union’s Horizon 2021 Research and Innovation Programme grant 101057619 and Mag-Tarmfonden (grant 1–23). The computations were partially enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Linköping University partially funded by the Swedish Research Council through grant agreement no. 2018–05973.